Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Idaho CIDP Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross of IdahoPolicy 5.01.667

    Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.667 alerts

    Get alerted when Policy 5.01.667 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for intravenous or subcutaneous immunoglobulin therapy and Vyvgart Hytrulo for individuals with chronic inflammatory demyelinating polyneuropathy. Coverage depends on diagnosis, objective impairment, treatment response, documentation, and product-specific requirements.

    Policy Summary
    PayerBlue Cross of Idaho
    PolicyTreatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateNot specified
    Key ActionFor commercial-plan SCIG requests, document use of preferred Cutaquig or Hizentra unless an approved exception is documented.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The policy added statements for subcutaneous immunoglobulin products Cutaquig and Hizentra, which may be medically necessary when specified criteria are met.

    12 weeksInitial approval duration
    1 yearImmunoglobulin continuation approval
    6 monthsVyvgart Hytrulo continuation approval
    18 yearsMinimum age for Vyvgart Hytrulo
    ≥1 INCATVyvgart Hytrulo response threshold

    Coverage Criteria

    Initial Immunoglobulin Therapy

    Initial requests for immunoglobulin therapy, including intravenous and subcutaneous administration, for treatment of CIDP may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • Individual has a diagnosis of CIDP with chronically progressive muscle weakness and/or sensory dysfunction in more than one limb for at least two (2) months.>= 2 months
    • ONE of the following confirms a demyelinating neuropathy:

      • ONE of the following electrodiagnostic findings:

        • Prolongation of motor distal latency in 2 nerves.2 nerves
        • Reduction of motor conduction velocity in 2 nerves.2 nerves
        • Prolongation of F-wave latency in 2 nerves.2 nerves
        • Absence of F-waves in at least 1 nerve.>= 1 nerve
        • Partial motor conduction block in at least 1 nerve.>= 1 nerve
        • Abnormal temporal dispersion in at least 2 nerves.>= 2 nerves
        • Distal compound muscle action potential (CMAP) duration increase in at least 1 nerve.>= 1 nerve
      • Cerebrospinal fluid (CSF) analysis shows albuminocytologic dissociation or elevated CSF protein with a white blood cell count of less than 10/mm3.< 10 WBC/mm3
    • Other causes of neuropathy or polyneuropathy have been ruled out, including but not limited to drug- or toxin-induced neuropathy, Lyme disease, immunoglobulin M (IgM) neuropathy, hereditary neuropathy, prominent sphincter disturbance, multifocal motor neuropathy, and diabetic neuropathy.
    • Documentation is provided that the individual demonstrates objective functional impairment from CIDP, including but not limited to requiring support to walk or upper-limb symptoms affecting or preventing functions such as zipping and buttoning, washing or brushing hair, using a knife and fork together, or handling small coins.

    Subcutaneous Immunoglobulin Product Preference

    For subcutaneous immunoglobulin therapy, coverage may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • Request is for ONE of the following:

      • Cutaquig.
      • Hizentra.
      • Individual has a documented contraindication, intolerance, or adverse response to all preferred products in the drug class, or has used the preferred products in the drug class with inadequate therapeutic response.

    Continuation Immunoglobulin Therapy

    Continuation or renewal requests for immunoglobulin therapy, including intravenous and subcutaneous administration, for treatment of CIDP may be considered medically necessary when the initial treatment conditions have been previously met AND ONE of the following continuation pathways is met:

    ALL of the following

    • ONE of the following continuation pathways:

      • For continued use after the initial trial: Documentation is provided that there is clinically significant and objective improvement in neurological symptoms on physical examination, such as an objective change in patient function that is clinically meaningful (for example, the patient can now work or perform tasks that they previously could not).
      • For ongoing maintenance therapy: Documentation is provided of sustained clinical improvement in neurological symptoms, such as maintenance of a clinically meaningful improvement in functional ability to perform tasks the patient previously could not, and status remains stable on the current dose, or worsening of symptoms occurs from a dose decrease or increase in dose intervals.

    Initial Vyvgart Hytrulo

    Initial requests for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for treatment of CIDP may be considered medically necessary when ALL of the following are met:

    ALL of the following

    • Individual is 18 years of age or older.>= 18 years
    • Individual has a diagnosis of CIDP with chronically progressive muscle weakness and/or sensory dysfunction in more than one limb for at least two (2) months.>= 2 months
    • ONE of the following confirms a demyelinating neuropathy:

      • ONE of the following electrodiagnostic findings:

        • Prolongation of motor distal latency in 2 nerves.

    Continuation Vyvgart Hytrulo

    Continuation or renewal requests for Vyvgart Hytrulo for treatment of CIDP may be considered medically necessary when the initial treatment conditions have been previously met AND ONE of the following continuation pathways is met:

    ALL of the following

    • ONE of the following continuation pathways:

      • Continued use after the initial trial

        • Documentation is provided of clinically significant improvement in neurological symptoms on physical examination demonstrated by improvement from baseline in INCAT (or adjusted INCAT) score of at least 1 point, improvement in I-RODS score of at least 4 points, or mean grip strength improvement of at least 8 kPa.INCAT >= 1 point; I-RODS >= 4 points; or grip strength >= 8 kPa
        • There is clinically significant and objective improvement in neurological symptoms on physical examination, such as an objective change in patient function that is clinically meaningful (for example, the patient can now work or perform tasks that they previously could not).

    Requests for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in CIDP may NOT be approved if used in combination with maintenance immunoglobulin treatment, eculizumab, ravulizumab, rituximab, zilucoplan, or rozanolixizumab.

    Coding and Authorization Parameters

    CPT CodesCPT
    90283Immune globulin (IgIV), human, for intravenous use.
    90284Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each.
    95851Range of motion measurements and report (separate procedure); each extremity (excluding hand) or each trunk section (spine).
    95852Range of motion measurements and report (separate procedure); hand, with or without comparison with normal side.
    96360Intravenous infusion, hydration; initial, 31 minutes to 1 hour.
    96361Intravenous infusion, hydration; each additional hour.
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
    96366Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour.
    HCPCS CodesHCPCS
    J1459Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg.
    J1460Injection, gamma globulin, intramuscular 1 cc (Gammar, Gamastan).
    J1551Injection, immune globulin (cutaquig), 100 mg.
    J1552Injection, immune globulin (alyglo), 500 mg.
    J1554Injection, immune globulin (asceniv), 500 mg.
    J1555Injection, immune globulin (cuvitru), 100 mg.
    J1556Injection, immune globulin (Bivigam), 500 mg.
    J1557Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg.
    J1558Injection, immune globulin (xembify), 100 mg.
    J1559Injection, immune globulin (Hizentra), 100 mg.
    1–10 of 19
    1/2
    Diagnosis CodesICD-10
    G61.81Chronic inflammatory demyelinating polyneuritis.
    Administration CodesICD-10
    3E013GCAdministration, introduction, subcutaneous tissue, percutaneous, other therapeutic substance.
    3E033GCAdministration, introduction, peripheral vein, percutaneous, other therapeutic substance.
    3E033WKAdministration, introduction, peripheral vein, immunotherapeutic, coded by qualifier.
    3E033WLAdministration, introduction, peripheral vein, immunotherapeutic, coded by qualifier.
    CIDP symptom duration
    RequirementCIDP symptoms must be present for at least 2 months.
    SymptomsChronically progressive muscle weakness and/or sensory dysfunction.
    DistributionSymptoms must affect more than one limb.
    CSF white blood cell count
    CSF white blood cell countLess than 10/mm3.
    CSF protein findingAlbuminocytologic dissociation or elevated CSF protein may support demyelinating neuropathy.

    Provider Requirements and Denial Risks

    Prior Authorization

    Initial Immunoglobulin Authorization

    For initial IVIG or SCIG authorization for CIDP, submit documentation showing the required clinical course, objective functional impairment, and evidence of demyelinating neuropathy. Other causes of neuropathy or polyneuropathy must also be excluded.

    • CIDP with chronically progressive muscle weakness and/or sensory dysfunction in more than one limb for at least 2 months.
    • Electrodiagnostic evidence of demyelination in the required nerves or qualifying CSF findings.
    • Objective impairment, such as requiring support to walk or difficulty with upper-limb activities.
    • Document exclusion of alternative causes, including drug/toxin exposure, Lyme disease, IgM neuropathy, hereditary neuropathy, prominent sphincter disturbance, multifocal motor neuropathy, and diabetic neuropathy.
    Prior Authorization

    Initial Vyvgart Hytrulo Authorization

    Initial Vyvgart Hytrulo authorization requires an adult CIDP diagnosis supported by demyelinating-neuropathy evidence, objective impairment, and a documented baseline outcome measure.

    Clinical Background

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, rare, immune-mediated inflammatory disorder affecting the myelin sheaths of peripheral nerves and nerve roots. It is characterized by progressive or relapsing muscle weakness and sensory impairment, with policy criteria emphasizing chronically progressive weakness and/or sensory dysfunction in more than one limb for at least 2 months.

    Clinical support includes evidence of peripheral nerve demyelination from qualifying electrodiagnostic findings or cerebrospinal fluid analysis. The policy recognizes plasma exchange, glucocorticoids, and IVIG as first-line options, with SCIG and Vyvgart Hytrulo as additional treatment options for appropriate individuals.

    Definitions and Abbreviations

    CSF evidence of demyelinating neuropathy
    CSF evidenceAlbuminocytologic dissociation or elevated CSF protein.
    White blood cell thresholdCSF white blood cell count must be less than 10/mm3.
    Clinical roleThese findings may confirm a demyelinating neuropathy for CIDP diagnosis.
    Functional outcome measures
    INCATInflammatory Neuropathy Cause and Treatment score, or adjusted INCAT score.
    I-RODSA functional outcome score documented at baseline and used to assess treatment response.
    Mean grip strength

    Initial Therapy Criteria

    Initial Immunoglobulin Therapy — IVIG and SCIG

    Initial immunoglobulin therapy, including IVIG and SCIG, may be considered medically necessary when all applicable clinical criteria are met.

    Initial immunoglobulin therapy

    • CIDP diagnosis and duration: The individual has a diagnosis of CIDP with chronically progressive muscle weakness and/or sensory dysfunction in more than one limb.At least 2 months
    • Evidence of demyelinating neuropathy

      • Electrodiagnostic findings: One of the following is present: prolongation of motor distal latency in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolongation of F-wave latency in 2 nerves; absence of F-waves in at least 1 nerve; partial motor conduction block in at least 1 nerve; abnormal temporal dispersion in at least 2 nerves; or distal CMAP duration increase in at least 1 nerve.

    Continuation Criteria

    Immunoglobulin Continuation

    Continuation or renewal of immunoglobulin therapy requires that the initial treatment conditions were previously met and that the applicable response criterion is documented.

    Immunoglobulin continuation response

    • Response after initial trial: Clinically significant and objective improvement in neurological symptoms on physical examination is documented.

      Examples include an objective, clinically meaningful change in function, such as the individual being able to work or perform tasks that were previously not possible.

    • Response during maintenance: Sustained clinical improvement in neurological symptoms is documented, with status stable on the current dose or worsening symptoms after a dose decrease or increase in dose intervals.

      Examples include maintaining a clinically meaningful improvement in the ability to perform previously impossible tasks.

    Vyvgart Hytrulo Continuation

    Step Therapy Requirements

    StepRequired prior therapyRequirement for initial Vyvgart Hytrulo coverage
    1Glucocorticoid therapy and intravenous or subcutaneous immune globulin therapyDocumentation of an inadequate response, intolerance, or contraindication to both therapies
    StepPreferred SCIG productException
    1Cutaquig or Hizentra for Blue Cross of Idaho commercial plan membersA documented contraindication, intolerance, or adverse response to all preferred products, or inadequate therapeutic response after use of all preferred products

    Site of Care

    Note

    Administer Vyvgart Hytrulo in the office

    Vyvgart Hytrulo is administered subcutaneously every 4 weeks by a healthcare professional in the office. Subsequent treatment cycles are based on clinical evaluation.

    Policy Summary
    PayerBlue Cross of Idaho
    PolicyTreatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateNot specified
    Key ActionFor commercial-plan SCIG requests, document use of preferred Cutaquig or Hizentra unless an approved exception is documented.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Authorization ParametersProvider Requirements and Denial RisksClinical BackgroundDefinitions and AbbreviationsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsSite of Care
    2 nerves
  1. Reduction of motor conduction velocity in 2 nerves.2 nerves
  2. Prolongation of F-wave latency in 2 nerves.2 nerves
  3. Absence of F-waves in at least 1 nerve.>= 1 nerve
  4. Partial motor conduction block in at least 1 nerve.>= 1 nerve
  5. Abnormal temporal dispersion in at least 2 nerves.>= 2 nerves
  6. Distal compound muscle action potential (CMAP) duration increase in at least 1 nerve.>= 1 nerve
  7. Cerebrospinal fluid (CSF) analysis shows albuminocytologic dissociation or elevated CSF protein with a white blood cell count of less than 10/mm3.< 10 WBC/mm3
  8. Other causes of neuropathy or polyneuropathy have been ruled out, including but not limited to drug- or toxin-induced neuropathy, Lyme disease, IgM neuropathy, hereditary neuropathy, prominent sphincter disturbance, multifocal motor neuropathy, and diabetic neuropathy.
  9. Documentation is provided that the individual demonstrates objective functional impairment from CIDP, including but not limited to requiring support to walk or upper-limb symptoms affecting or preventing functions such as zipping and buttoning, washing or brushing hair, using a knife and fork together, or handling small coins.
  10. Documentation of a baseline INCAT (or adjusted INCAT) score, I-RODS score, or mean grip strength measure.
  11. Documentation demonstrates that the individual has had an inadequate response to, is intolerant of, or has a contraindication to glucocorticoid therapy.
  12. Documentation demonstrates that the individual has had an inadequate response to, is intolerant of, or has a contraindication to intravenous or subcutaneous immune globulin therapy.
  13. Vyvgart Hytrulo is prescribed by or in consultation with a neurologist.
  14. For ongoing maintenance therapy: Documentation is provided of sustained clinical improvement in neurological symptoms, such as maintenance of a clinically meaningful improvement in functional ability to perform tasks the patient previously could not, and status remains stable on the current dose, or worsening of symptoms occurs from a dose decrease or increase in dose intervals.
    ApplicationThe CSF finding is used as evidence of a demyelinating neuropathy in CIDP.
    Vyvgart Hytrulo minimum age
    Minimum age18 years or older.
    TreatmentVyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc).
    IndicationTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
    INCAT improvement for Vyvgart Hytrulo continuation
    Required improvementAt least 1 point improvement from baseline on the INCAT or adjusted INCAT score.
    Continuation settingUsed to document response after the initial Vyvgart Hytrulo trial.
    Additional requirementThe improvement must be accompanied by clinically significant and objective neurological improvement.
    I-RODS improvement for Vyvgart Hytrulo continuation
    Required improvementAt least 4 points improvement from baseline on the I-RODS score.
    Continuation settingUsed to document response after the initial Vyvgart Hytrulo trial.
    Additional requirementThe improvement must be accompanied by clinically significant and objective neurological improvement.
    Mean grip strength improvement for Vyvgart Hytrulo continuation
    Required improvementAt least 8 kPa improvement from baseline in mean grip strength.
    Continuation settingUsed to document response after the initial Vyvgart Hytrulo trial.
    Additional requirementThe improvement must be accompanied by clinically significant and objective neurological improvement.
    • Individual must be at least 18 years old and have CIDP with progressive weakness and/or sensory dysfunction in more than one limb for at least 2 months.
    • Submit qualifying electrodiagnostic or CSF evidence of demyelination and documentation of objective functional impairment.
    • Record a baseline INCAT or adjusted INCAT score, I-RODS score, or mean grip strength measure.
    • Initial approval duration is 12 weeks.

    Unsupported block type: prior_auth

    Documentation Required

    Required Prior Therapy History

    Before Vyvgart Hytrulo is authorized, document an inadequate response to, intolerance of, or contraindication to both glucocorticoid therapy and IVIG or SCIG therapy. The medication must be prescribed by or in consultation with a neurologist.

    • Include the therapy name, treatment dates or duration, clinical response, and the reason treatment was inadequate, not tolerated, or contraindicated.
    • Document prior treatment history for both glucocorticoids and intravenous or subcutaneous immune globulin.
    Step Therapy

    Preferred SCIG Products

    For SCIG requests under the Blue Cross of Idaho commercial plan, request a preferred product unless the record supports an exception.

    • Preferred products are Cutaquig or Hizentra.
    • If requesting another SCIG product, document a contraindication, intolerance, or adverse response to all preferred products, or inadequate therapeutic response after use of the preferred products.
    Documentation Required

    CIDP Diagnostic Documentation

    Support the CIDP diagnosis with clinical documentation of progressive weakness or sensory dysfunction and objective evidence of peripheral-nerve demyelination. Clinical symptoms alone are not sufficient to confirm CIDP.

    • Provide qualifying electrodiagnostic findings, such as slowed conduction, prolonged distal or F-wave latency, absent F-waves, conduction block, temporal dispersion, or increased distal CMAP duration.
    • Qualifying CSF may show albuminocytologic dissociation or elevated protein with fewer than 10 white blood cells/mm3.
    • When findings are nondiagnostic, diagnostic support may include nerve biopsy and exclusion of similar disorders; CSF analysis may be used when clinically appropriate.
    Documentation Required

    Vyvgart Hytrulo Initial Documentation

    For an initial Vyvgart Hytrulo request, include the patient’s age, CIDP treatment history, baseline outcome measure, prescriber information, and the clinical findings supporting medical necessity.

    • Document baseline INCAT or adjusted INCAT, I-RODS, or mean grip strength before treatment.
    • Include objective functional impairment and qualifying demyelinating-neuropathy evidence.
    • Document inadequate response, intolerance, or contraindication to glucocorticoids and IVIG or SCIG.
    • Identify the neurologist who prescribed or is consulting on Vyvgart Hytrulo.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Documentation Required

    Support the CIDP Diagnosis

    A CIDP diagnosis that is not adequately supported should be supplemented with evidence of peripheral-nerve demyelination and exclusion of disorders that mimic CIDP.

    • Provide electrodiagnostic findings demonstrating features such as temporal dispersion, reduced CMAP amplitude, slowed conduction velocity, or partial conduction block.
    • Consider nerve biopsy or CSF analysis when clinically appropriate and electrodiagnostic findings are nondiagnostic.
    • Document evaluation for similar disorders because no single laboratory test confirms CIDP.
    Denial Risk

    Alternative Neuropathy Cause Not Excluded

    Authorization may be denied when the record does not show that alternative causes of neuropathy or polyneuropathy were ruled out.

    • Address drug- or toxin-induced neuropathy, Lyme disease, IgM neuropathy, hereditary neuropathy, prominent sphincter disturbance, multifocal motor neuropathy, diabetic neuropathy, and other clinically relevant alternatives.
    Denial Risk

    Required Prior Therapies Not Documented

    An initial Vyvgart Hytrulo request may be denied when required prior therapy history is absent or does not establish inadequate response, intolerance, or contraindication.

    • The record must address both glucocorticoid therapy and IVIG or SCIG therapy.
    • Include treatment details and the clinical basis for inadequate response, intolerance, or contraindication.
    Denial Risk

    Prohibited Combination Therapy

    Vyvgart Hytrulo may not be approved for CIDP when used in combination with prohibited maintenance therapies.

    • Do not combine Vyvgart Hytrulo with maintenance immunoglobulin treatment, eculizumab, ravulizumab, rituximab, zilucoplan, or rozanolixizumab.
    Denial Risk

    Insufficient Continuation Response

    A continuation request may be denied when the submitted record does not demonstrate the required objective and clinically meaningful response or sustained benefit.

    • For Vyvgart Hytrulo, document the applicable INCAT, I-RODS, or mean grip strength improvement threshold plus objective functional improvement.
    • For immunoglobulin therapy, document objective neurological improvement after the initial trial or sustained meaningful benefit during maintenance.
    • Explain any worsening after dose reduction or increased dosing intervals when relying on that maintenance criterion.
    Denial Risk

    Preferred SCIG Requirement Not Met

    A nonpreferred SCIG request may be denied unless the provider documents the required exception to the Cutaquig or Hizentra preference.

    • Use Cutaquig or Hizentra when clinically appropriate.
    • For an exception, document contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products.
    Billing Rule

    Codes Do Not Guarantee Coverage

    Codes and coding guidance are provided for general reference only and do not guarantee member coverage or provider reimbursement.

    • Coverage depends on the member-specific benefit plan, written policy terms, legal requirements, and other applicable policies and guidelines.
    • The inclusion of a code does not create a right to coverage or payment, and exclusion of a code does not necessarily mean coverage or reimbursement is unavailable.
    A strength measure documented at baseline and used to assess treatment response.
    Ongoing maintenance therapy
    DefinitionTreatment after the initial trial when clinically meaningful improvement is maintained.
    Stable treatmentThe individual remains stable on the current dose.
    Dose change responseSymptoms worsen after dose reduction or increased dosing intervals.
    Black box warnings
    Immunoglobulin thrombosis warningIntravenous and subcutaneous immunoglobulins carry a black box warning for thrombosis.
    IVIG renal warningIVIG carries a black box warning for renal dysfunction and acute renal failure.
    Additional safety concernsWarnings and precautions include severe hypersensitivity or anaphylactic reactions in certain IgA-deficient individuals, aseptic meningitis, hemolytic anemia, and pulmonary adverse reactions.
    Chronic inflammatory demyelinating polyneuropathy (CIDP)
    DefinitionAn acquired, rare, immune-mediated inflammatory peripheral nerve disorder.
    Anatomic involvementThe disorder affects the myelin sheaths of peripheral nerves and nerve roots.
    Clinical patternIt may follow a relapsing-remitting or progressive course with symmetric proximal and distal muscle weakness, sensory impairment, impaired balance, and difficulty walking.
    Albuminocytologic dissociation
    DefinitionA cerebrospinal fluid pattern in which elevated protein is present without a corresponding increase in cells.
    Diagnostic useAlbuminocytologic dissociation is listed in the diagnostic criteria for CIDP according to EAN/PNS guidelines.
    Testing contextCSF analysis may be performed when clinical and electrophysiologic findings are nondiagnostic.
    IVIG/SCIG
    IVIGImmunoglobulin administered intravenously.
    SCIGImmunoglobulin administered subcutaneously.
    Clinical useBoth are treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP).
    aINCAT
    AbbreviationaINCAT.
    MeaningAdjusted Inflammatory Neuropathy Cause and Treatment.
    Policy useThe adjusted INCAT score may be used as a baseline and treatment-response measure.
    CIDP
    AbbreviationCIDP.
    MeaningChronic inflammatory demyelinating polyradiculoneuropathy.
    Policy conditionThe policy addresses treatment of CIDP with immunoglobulin therapy and Vyvgart Hytrulo.
    HR
    AbbreviationHR.
    MeaningHazard ratio.
    ContextThe abbreviation is used in the policy's review of evidence.
    mITT
    AbbreviationmITT.
    MeaningModified intention-to-treat.
    ContextThe abbreviation is used in the policy's review of evidence.
    SC
    AbbreviationSC.
    MeaningSubcutaneous.
    Policy applicationSC describes subcutaneous immunoglobulin administration and therapy.
    CSF findings: Cerebrospinal fluid analysis shows albuminocytologic dissociation or elevated CSF protein with a white blood cell count less than 10/mm3.WBC <10/mm3
  15. Alternative causes excluded: Other causes of neuropathy or polyneuropathy have been ruled out.

    Includes, but is not limited to, drug- or toxin-induced neuropathy, Lyme disease, IgM neuropathy, hereditary neuropathy, prominent sphincter disturbance, multifocal motor neuropathy, and diabetic neuropathy.

  16. Objective functional impairment from CIDP is documented.

    Examples include requiring support to walk or upper-limb symptoms affecting or preventing the ability to perform functions such as using zips and buttons, washing or brushing hair, using a knife and fork together, or handling small coins.

  17. SCIG product preference when applicable

    • Preferred product: For a Blue Cross of Idaho commercial plan member requesting SCIG, the requested product is Cutaquig or Hizentra.
    • Documented exception: For a Blue Cross of Idaho commercial plan member requesting SCIG, there is a documented contraindication, intolerance, or adverse response to all preferred products in the drug class, or inadequate therapeutic response after use of the preferred products.
  18. Initial Vyvgart Hytrulo

    Initial Vyvgart Hytrulo may be considered medically necessary when all product-specific clinical, treatment-history, measurement, and specialist criteria are met.

    • Age: The individual is 18 years of age or older.≥18 years
    • CIDP diagnosis and duration: The individual has a diagnosis of CIDP with chronically progressive muscle weakness and/or sensory dysfunction in more than one limb.At least 2 months
    • Demyelinating neuropathy evidence

      • Electrodiagnostic findings: One of the following is present: prolongation of motor distal latency in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolongation of F-wave latency in 2 nerves; absence of F-waves in at least 1 nerve; partial motor conduction block in at least 1 nerve; abnormal temporal dispersion in at least 2 nerves; or distal CMAP duration increase in at least 1 nerve.
      • CSF findings: Cerebrospinal fluid analysis shows albuminocytologic dissociation or elevated CSF protein with a white blood cell count less than 10/mm3.WBC <10/mm3
    • Alternative causes excluded: Other causes of neuropathy or polyneuropathy have been ruled out.
    • Objective functional impairment from CIDP is documented.
    • Baseline measurement: A baseline INCAT or adjusted INCAT score, I-RODS score, or mean grip strength measure is documented.
    • Prior glucocorticoid therapy: The individual has had an inadequate response to, is intolerant of, or has a contraindication to glucocorticoid therapy.
    • Prior immunoglobulin therapy: The individual has had an inadequate response to, is intolerant of, or has a contraindication to intravenous or subcutaneous immune globulin therapy.
    • Specialist involvement: Vyvgart Hytrulo is prescribed by or in consultation with a neurologist.

    Continuation or renewal of Vyvgart Hytrulo requires that the initial treatment conditions were previously met and that the applicable response criterion is documented.

    Vyvgart Hytrulo continuation response

    • Response after initial trial: Clinically significant improvement in neurological symptoms on physical examination is documented, with improvement from baseline in INCAT or adjusted INCAT, I-RODS, or mean grip strength.INCAT ≥1 point; I-RODS ≥4 points; or mean grip strength ≥8 kPa

      The improvement must be clinically significant and objective, such as the individual being able to work or perform tasks that were previously not possible.

    • Response during maintenance: Sustained clinical improvement in neurological symptoms is documented, with status stable on the current dose or worsening symptoms after a dose decrease or increase in dose intervals.

      Examples include maintaining a clinically meaningful improvement in the ability to perform previously impossible tasks.